
|Articles|May 21, 2019
Xcenda Announces Acquisition of Dymaxium
Advertisement
Xcenda, a part of AmerisourceBergen, has acquired Dymaxium, a market access partner specializing in the exchange of evidence and information between payers and life science companies.
This acquisition will further simplify and streamline the necessary communication of clinical evidence and health economic information between manufacturers and population health decision makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial
2
FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma
3
Novartis to Layoff 322 NJ Employees: Report
4
Pharmaceutical Executive Daily: FDA Approves Subcutaneous Sarclisa Escena
5




